Certara, Inc.
No SEC Form 4 filings for $CERT in the last 30 days.
See all $CERT insider activity →UBS downgraded Certara to 'Neutral' from 'Buy' and set a $10 price target. The company's stock is currently trading at $9.26, up 1.42% over 5 days. Certara recently reported Q2 revenue of $64.6M, exceeding estimates. The downgrade may impact investor sentiment and trading activity.
Certara (CERT) reported Q2 2026 results with software revenue up 4% to $48.8M and bookings up 9%, but a net loss of $6.1M due to services decline and higher costs. The company cut 5% of its workforce, saving $13M annually, and reaffirmed full-year revenue guidance of $367M-$382M. Certara also expanded its share repurchase program by $50M.
MindWalk Holdings Corp. (HYFT) reported a 46% revenue increase to C$15.6M, with improved margins and narrowed losses. The company focuses on AI-enabled drug discovery, emphasizing its data and systems of record. Comparatively, Veeva Systems (VEEV) rose after strong earnings, while Certara (CERT) and Recursion (RXRX) fell due to missed expectations, highlighting market preference for proprietary data.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CERT (Certara, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent CERT coverage spans earnings, financial news and corporate actions.
The downgrade signals reduced confidence in Certara's near‑term outlook, likely prompting sell pressure.
Earnings miss and high short interest may pressure the stock, but software growth and buyback authorization provide upside catalysts.
Missed earnings and share decline suggest short‑term downside.
Positive earnings beat and higher production suggest near‑term upside, but guidance remains unchanged.
Guidance and margin range reset around the divestiture, with buyback authorization adding a near-term capital return signal.
AlphAI scores every news story that mentions CERT with an AI model for sentiment and relevance, and aggregates insider trades from Certara, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS downgraded Certara to 'Neutral' from 'Buy' and set a $10 price target. The company's stock is currently trading at $9.26, up 1.42% over 5 days. Certara recently reported Q2 revenue of $64.6M, exceeding estimates. The downgrade may impact investor sentiment and trading activity.
1 min readCertara (CERT) reported Q2 2026 results with software revenue up 4% to $48.8M and bookings up 9%, but a net loss of $6.1M due to services decline and higher costs. The company cut 5% of its workforce, saving $13M annually, and reaffirmed full-year revenue guidance of $367M-$382M. Certara also expanded its share repurchase program by $50M.
2 min readMindWalk Holdings Corp. (HYFT) reported a 46% revenue increase to C$15.6M, with improved margins and narrowed losses. The company focuses on AI-enabled drug discovery, emphasizing its data and systems of record. Comparatively, Veeva Systems (VEEV) rose after strong earnings, while Certara (CERT) and Recursion (RXRX) fell due to missed expectations, highlighting market preference for proprietary data.
3 min readCerrado Gold reported Q2 2026 results: 15,415 GEO produced at AISC of $1,933/oz, $28.2M adjusted EBITDA, and $25.3M cash. Annual guidance maintained at 50,000-60,000 GEO. MDN mine saw production increases, while Lagoa Salgada and Mont Sorcier projects advanced. Management to host call August 19.
2 min readCertara, Inc. reported Q2 2026 updates on its shift to specialist, scientist-led sales and a divestiture of its regulatory and medical writing business. Software revenue is 53% of total, up from 40% two years ago. Full-year revenue guidance is 0% to 4%, with adjusted EBITDA margin guided at 29% to 31%. Net loss from continuing operations was $6.1M. A new $50M share repurchase was authorized.
7 min readCertara (CERT) reported Q2 2026 revenue of $93.3 million, up 1% YoY, with software revenue $48.8 million (+4%) and services $44.5 million (-3%). Total bookings were $98.3 million (+1%). Adjusted EBITDA was $26.2 million (28.1% margin). 2026 guidance: revenue $367-$382 million and adjusted EPS $0.31-$0.36. The company completed a divestiture and is integrating AI, and announced NVIDIA partnership.
7 min readCertara, Inc. (CERT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Certara Reports Second Quarter 2026 Financial Results A ppoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026 revenue guid
6 min readCertara, Inc. (CERT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 4, 2026, Certara, Inc. (the “Company”) announced the departure of Leif E. Pedersen from his role as the Company’
2 min readCerrado Gold said it will extend the completion timing of the Mont Sorcier bankable feasibility study to incorporate optimization work. The company plans mine-plan changes to reduce strip ratio, review tailings dam and CAPEX/OPEX amid inflation, and assess a 65% vs 67% iron concentrate trade-off. It expects ESIA filing in Q2 2027 and permits around year-end 2028.
4 min readCertara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI drug development platform, adding agentic frameworks to support tasks across dosing optimization, clinical-data analysis, ADMET evaluation and regulatory evidence. Silo Pharma’s subsidiary QwikAgents joined Nvidia’s Developer Program to expand its autonomous AI agent platform. NVDA shares were up; Certara and Silo were down at publication.
4 min read
